ALK-Abello Tops Q4 Estimates and Revives Dividend with Confident 2026 Outlook

Danish biotech ALK-Abello A/S (CSE: ALKB) turned in a stronger-than-expected performance for the fourth quarter, putting a smile on investors' faces with sales clocking in at DKK1.73 billion, outpacing consensus forecasts by 3%. The company's earnings before interest and taxes (EBIT) also beat estimates, reaching DKK387 million-5% ahead of what analysts had penciled in.

The driving force behind this upside came from robust European tablet sales, which soared 6% beyond expectations, along with a 14% uplift in other product categories. While overall tablet sales nudged 2% above estimates, subcutaneous and sublingual immunotherapy drops held steady at DKK607 million, meeting analyst predictions.

Margins saw a modest boost, with the EBIT margin hitting 22.3% compared to a consensus of 21.9%. However, this margin expansion was partly tempered by an uptick in operating expenses and higher taxes, causing net income to fall short of estimates despite the strong top-line and operating performance.

Notably, ALK-Abello announced a dividend proposal of DKK1.6 per share, marking its first payout since 2017. This move is reflective of the company's net debt position and signals a renewed focus on shareholder returns after a long hiatus from dividends.

Looking ahead, the firm projects revenue growth between 11% and 15% at constant exchange rates for 2026, translating into revenues ranging from DKK6.9 billion to DKK7.2 billion. Analysts' consensus numbers are slightly below the midpoint of this range, at around DKK7.04 billion. Meanwhile, ALK-Abello expects an EBIT margin close to 25%, aligning with market forecasts.

The gross margin is anticipated to take a mild hit, as gains from the higher volume of European tablet sales are offset by lower-margin sales linked to partnership deals. On the product front, the neffy brand has carved out an 18% value share in Germany within just six months, bolstered by secured reimbursement. However, regulatory approval in Canada is progressing more sluggishly than initially hoped.

In leadership changes, Henriette Mersebach plans to step down as head of research and development on February 23. The company seeks a successor with a fresh profile, while former R&D head Henrik Jacobi steps in as special advisor to the CEO and executive team during the transition. A search for a new R&D chief is already underway.

The quarter's results and guidance point to steady progress and a willingness to return capital to shareholders after years of reinvestment. Whether ALK-Abello can maintain this momentum in the face of regulatory delays and margin pressures remains a key question for the year ahead.